Novel targeted therapies and immunotherapy for advanced thyroid cancers
Abstract Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most anaplastic types, remain resistant to standard treatment options, including radioactive iodine (RAI). In addition, a...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-02-01
|
Series: | Molecular Cancer |
Online Access: | http://link.springer.com/article/10.1186/s12943-018-0786-0 |